Journal of Parasitic Diseases

, Volume 40, Issue 3, pp 760–767 | Cite as

The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccine

  • Narges Khabazzadeh Tehrani
  • Mehdi Mahdavi
  • Fatemeh Maleki
  • Somayeh Zarrati
  • Fatemeh TabatabaieEmail author
Original Article


Leishmaniasis is a parasitic disease caused by several species of the genus Leishmania. Montanide ISA 70 is an adjuvant composed of a natural metabolizable oil and a very refined emulsifier from the manide monooleate family. The TSA (thiol-specific antioxidant) is a important antigen of Leishmania major. The purpose of this work was protein-vaccine efficacy as an protection and excellent candidate in the presence Montanide. The expression of recombinant protein was confirmed with SDS (sodium dodecyl sulfate) page and Western bloting. 48 BALB/c mice were divided into four groups (TSA/Freund,TSA/Alum + BCG, TSA/Montanide and PBS groups) and immunized with 20 μg of vaccine subcutaneously three times intervals on days 0, 14 and 28. The mice were challenged with parasite 21 days after final immunization. The lymphocyte proliferation was evaluated with Brdu method. Cytokines and also total antibody and subclasses were evaluated with ELISA method. The vaccine formulated with the recombinant TSA protein with Montanide induced lymphocytes proliferation cytokines and total antibody and subclasses as compared with the control group.


BCG TSA Montanide Leishmaniasis Vaccine IFN-γ 



We would like to thank of Iran University of Medical Sciences and Tehran University of Medical sciences for Financial Supports this work.

Conflict of interest

We declare no conflicts of interest.


  1. Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi KA (2004) Comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L.major. Vaccine 22:1631–1639CrossRefPubMedGoogle Scholar
  2. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J et al (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7:e35671CrossRefPubMedCentralPubMedGoogle Scholar
  3. Aucouturier J, Dupuis L, Ganne V (2001) Adjuvants designed for veterinary and human vaccines. Vaccine 19:2666–2672CrossRefPubMedGoogle Scholar
  4. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V (2002) Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 1:111–118CrossRefPubMedGoogle Scholar
  5. Benhnini F, Chenik M, Laouini D, Louzir H, Cazenave PA, Dellagi K (2009) Comparative evaluation of two vaccine candidates against experimental leishmaniasis due to Leishmania major infection in four inbred mouse strains. Clin Vaccine Immunol 16:1529–1537CrossRefPubMedCentralPubMedGoogle Scholar
  6. Bradford, MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefPubMedPubMedCentralGoogle Scholar
  7. Buffer PA, Sulahian A, Garin YJF, Nassar N, Derouin F (1995) Culture microtitration :a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 216:7–8Google Scholar
  8. Campos-Neto A (2005) What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? Braz j Med Biol Res = Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica [et al]; 38:979–984Google Scholar
  9. Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA et al (2001) Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69:4103–4108CrossRefPubMedCentralPubMedGoogle Scholar
  10. Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG (2002) Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect Immun 70:2828–2836CrossRefPubMedCentralPubMedGoogle Scholar
  11. Chae HZ, Kim IH, Kim K, Rhee SG (1993) Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae. J Biol Chem 268:16815–16821PubMedGoogle Scholar
  12. Chae HZ, Chung SJ, Rhee SG (1994a) Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem 269:27670–27678PubMedGoogle Scholar
  13. Chae HZ, Robison K, Poole LB, Church G, Storz G, Rhee SG (1994b) Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci U S A 91:7017–7021CrossRefPubMedCentralPubMedGoogle Scholar
  14. Coler, RN, Reed, SG (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21:244–249CrossRefPubMedGoogle Scholar
  15. Douba MD, Abbas O, Wali A, Nassany J, Aouf A, Tibbi MS et al (2012) Chronic cutaneous leishmaniasis, a great mimicker with various clinical presentations: 12 years experience from Aleppo. J Eur Acad Dermatol Venereol 26:1224–1229CrossRefPubMedGoogle Scholar
  16. Farahmand M, Nahrevanian H, Shirazi HA, Naeimi S, Farzanehnejad Z (2011) An overview of a diagnostic and epidemiologic reappraisal of cutaneous leishmaniasis in Iran. Braz J Infect Dis 15:17–21CrossRefPubMedGoogle Scholar
  17. Handman E (2001) Leishmaniasis :current status of vaccine development. Clin Microbiol Rev 14:229–243CrossRefPubMedCentralPubMedGoogle Scholar
  18. James SL, Nacy C (1993) Effector functions of activated macrophages against parasites. Curr Opin Immunol 5:518–523CrossRefPubMedGoogle Scholar
  19. Joshua MM, John CM, Michael MG (2010) A review of adjuvants for leishmania vaccine candidates. J Biomed Res 24:16–25CrossRefGoogle Scholar
  20. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F (2006) Leishmaniasis vaccine candidates for development: a global overview. IndianJ Med Res 123:423–438Google Scholar
  21. Khoshgoo N, Zahedifarda F, Azizia H, Taslimia Y, Alonsoc MJ, Rafati S (2008) Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals. Vaccine 26:5822–5829CrossRefPubMedGoogle Scholar
  22. Masina S, Gicheru MM, Demotz SO, Fasel NJ (2003) Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen. J Infect Dis 15:1250–1257CrossRefGoogle Scholar
  23. Mauel J (2002) Vaccination against Leishmania infections. Curr Drug Targets Immune Endocr Metabol Disord 2:201–226CrossRefPubMedGoogle Scholar
  24. Mehlotra, RK (1996) Antioxidant defense mechanisms in parasitic protozoa. Crit Rev Microbiol 22:295–314CrossRefPubMedGoogle Scholar
  25. Mendez S, Belkaid Y, Seder RA, Sacks D, Sender R (2002) Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702–3708CrossRefPubMedGoogle Scholar
  26. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, Wang ZE et al (1995) Expression cloning of a protective Leishmania antigen. Science 268:563CrossRefPubMedGoogle Scholar
  27. Netto, LES, Chae,H.Z, Kang, SW, Rhee,S.G, Stadtman, ER (1996) Removal of hydrogen peroxide by thiol-specific antioxidant enzyme [TSA] is involved with its antioxidant properties. TSA possesses thiol peroxidase activity. J Biol Chem 271:15315–15321CrossRefGoogle Scholar
  28. Ovendale PJ, Martin TI, Webb JR, Campos-Neto A, Reed SG, Badaro R et al (1998) Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66:3279–3289PubMedCentralPubMedGoogle Scholar
  29. Qiu Q, Yuan-HuWang R, Jiao X, Jin B, Sugauchi F, Grandinetti T et al (2008) Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine 26:5527–5534CrossRefPubMedCentralPubMedGoogle Scholar
  30. Rafati S, Zahedifard F, Nazgouee F (2006) Prime–boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24:2169–2175CrossRefPubMedGoogle Scholar
  31. Rosado-Vallado M, Mut-Martin M, Garsia-Miss M, Dumonteil E (2005) Aluminium phosphate potentiates the efficacy of DNA vaccine against Leishmania Mexicana. Vaccine 23:5372–5379CrossRefPubMedGoogle Scholar
  32. Sasaki S, Takeshita F, Xin KQ, Ishii N, Okuda K (2003) Adjuvant formulation and delivery systems for DNA vaccines. Methods 31:243–254CrossRefPubMedGoogle Scholar
  33. Tabatabaie F, Ghaffari far F, Dalimi A, Sharifi Z, Zavaran Hoseini A (2007) Cloning and sequencing of leishmania major thiol-specific antioxidant antigen [TSA] gene. Iran J Parasitol 2:30–41Google Scholar
  34. Toledo H, Baly A, Castro O, Resik S, Laferte J, Rolo F et al (2001) A phase I clinical trial of a multi-epitope polypeptide TAB 9 combined with Montanide ISA720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 19:4328–4336CrossRefPubMedGoogle Scholar
  35. Von Stebut E (2007) Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol 17:115–122Google Scholar
  36. Webb JR, Campos-Neto A, Ovendale PJ, Martin TI, Stromberg EJ, Badaro R et al (1998) Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66:3279–3289PubMedCentralPubMedGoogle Scholar

Copyright information

© Indian Society for Parasitology 2014

Authors and Affiliations

  • Narges Khabazzadeh Tehrani
    • 1
  • Mehdi Mahdavi
    • 2
  • Fatemeh Maleki
    • 3
  • Somayeh Zarrati
    • 1
  • Fatemeh Tabatabaie
    • 4
    Email author
  1. 1.Biology Dept, Science &Research BranchIslamic Azad UniversityTehranIran
  2. 2.Immunology DeptPasteur Institute of IranTehranIran
  3. 3.Faculty of Allied MedicineIran University of Medical Sciences (IUMS)TehranIran
  4. 4.Parasitology and Mycology Dept., School of MedicineIran University of Medical Sciences(IUMS)TehranIran

Personalised recommendations